DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the Metastatic Castration-Resistant Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Castration-Resistant Prostate Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
Request a sample and discover the recent advances in Metastatic Castration-Resistant Prostate Cancer treatment drugs @ Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook Report
Metastatic Castration-Resistant Prostate Cancer Overview
Prostate cancer (PCa) is one of the most prevalent malignancies in the world and the third most common cause of male cancer-related death in the United States of America (USA). The majority of men with newly diagnosed PCa present with localized disease and undergo radical prostatectomy and/or radiological therapy, followed by androgen deprivation therapy (ADT).
Depending on the grade of the cancer, a variable percentage of these patients experience progression to castration-resistant prostate cancer (CRPC) within 10 years. CRPC was previously named “hormone-refractory prostate cancer” and “androgen-independent prostate cancer”. However, because castration treatments including ADT were ineffective, these cancers still showed reliance upon hormones for androgen receptor (AR) activation.
Metastatic Castration-Resistant Prostate Cancer Emerging Drugs Profile
SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.
Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.
Find out more about Metastatic Castration-Resistant Prostate Cancer treatment drugs @ Drugs for Metastatic Castration-Resistant Prostate Cancer Treatment
Metastatic Castration-Resistant Prostate Cancer Therapeutics Assessment
There are approx. 75+ key Metastatic Castration-Resistant Prostate Cancer companies which are developing the therapies Metastatic Castration Resistant Prostate cancer. The Metastatic Castration-Resistant Prostate Cancer companies which have their Metastatic Castration Resistant Prostate cancer drug candidates in the most advanced stage, i.e phase III include Clovis Oncology.
DelveInsight’s Metastatic Castration-Resistant Prostate Cancer pipeline report covers around 75+ products under different phases of clinical development like
Learn more about the emerging Metastatic Castration-Resistant Prostate Cancer pipeline therapies @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials
Metastatic Castration Resistant Prostate cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Metastatic Castration-Resistant Prostate Cancer Products have been categorized under various Molecule types such as
Metastatic Castration-Resistant Prostate Cancer Companies
Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
Dive deep into rich insights for new drugs for Metastatic Castration-Resistant Prostate Cancer Treatment, visit @ Metastatic Castration-Resistant Prostate Cancer Drugs
Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
For further information on the Metastatic Castration-Resistant Prostate Cancer Pipeline Therapeutics, reach out @ Metastatic Castration-Resistant Prostate Cancer Treatment Drugs
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/